Various drugs have been proposed for inhibiting metabolic and/or mitochondrial pathways in tumor models and clinical trials, including glycolysis inhibitors (blocking hexokinase 2, phosphofructokinase 2, pyruvate kinase, lactate dehydrogenase A, or pyruvate dehydrogenase kinase) [1,8], oxidative phosphorylation (OXPHOS) inhibitors (via drugs such as metformin, atovaquone, or arsenic acid) [1,9], nucleic acid metabolism inhibitors [10], or inhibitors of abnormally induced fatty acid synthesis, oxidation, or uptake [1,11]. The gene discussed is LDHA; the disease is neoplasm.